Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FGBR4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,598
Award facts
- Contract value 100% obligated
- $20,598.16 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $20,598.16 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Stelara 90 mg/mL syringes. The delivery order was issued on January 14, 2026, with an ultimate completion date of February 5, 2026, and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc. will perform this work at its Park Ridge facility and will receive no subcontractor support on this award.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. That underlying IDC, valued at $499,999,999 and awarded on November 13, 2025, positions DMS Pharmaceutical Group as one of multiple regional prime vendor contractors supporting the $30.3 billion PPV-G GEN V acquisition strategy. The contract structure authorizes the Defense Logistics Agency to issue firm fixed-price delivery orders for comprehensive pharmaceutical products, including biologics and medical consumables, to support recurring medical supply needs of military healthcare facilities worldwide, with DMS Pharmaceutical Group's established performance on numerous prior delivery orders demonstrating its capability to fulfill the specialized pharmaceutical requirements of Department of Defense healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FGBR4?
SPE2DR26FGBR4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 14, 2026.
How much is contract SPE2DR26FGBR4 worth?
The government has obligated $20,598 on SPE2DR26FGBR4.
Is contract SPE2DR26FGBR4 an order under another contract?
Yes. SPE2DR26FGBR4 is a delivery order under SPE2DR25D9315, an indefinite delivery contract.
Was contract SPE2DR26FGBR4 competed?
The extent of competition for SPE2DR26FGBR4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award